Literature DB >> 21905170

Concise review: Human cell engineering: cellular reprogramming and genome editing.

Prashant Mali1, Linzhao Cheng.   

Abstract

Cell engineering is defined here as the collective ability to both reset and edit the genome of a mammalian cell. Until recently, this had been extremely challenging to achieve as nontransformed human cells are significantly refractory to both these processes. The recent success in reprogramming somatic cells into induced pluripotent stem cells that are self-renewable in culture, coupled with our increasing ability to effect precise and predesigned genomic editing, now readily permits cellular changes at both the genetic and epigenetic levels. These dual capabilities also make possible the generation of genetically matched, disease-free stem cells from patients for regenerative medicine. The objective of this review is to summarize the key enabling developments on these two rapidly evolving research fronts in human cell engineering, highlight unresolved issues, and outline potential future research directions.
Copyright © 2011 AlphaMed Press.

Entities:  

Mesh:

Year:  2012        PMID: 21905170      PMCID: PMC4696036          DOI: 10.1002/stem.735

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  63 in total

1.  Hypoxia enhances the generation of induced pluripotent stem cells.

Authors:  Yoshinori Yoshida; Kazutoshi Takahashi; Keisuke Okita; Tomoko Ichisaka; Shinya Yamanaka
Journal:  Cell Stem Cell       Date:  2009-08-27       Impact factor: 24.633

2.  Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution.

Authors:  Nimet Maherali; Rupa Sridharan; Wei Xie; Jochen Utikal; Sarah Eminli; Katrin Arnold; Matthias Stadtfeld; Robin Yachechko; Jason Tchieu; Rudolf Jaenisch; Kathrin Plath; Konrad Hochedlinger
Journal:  Cell Stem Cell       Date:  2007-06-07       Impact factor: 24.633

3.  Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease.

Authors:  Jizhong Zou; Prashant Mali; Xiaosong Huang; Sarah N Dowey; Linzhao Cheng
Journal:  Blood       Date:  2011-08-31       Impact factor: 22.113

4.  Cancer-related epigenome changes associated with reprogramming to induced pluripotent stem cells.

Authors:  Joyce E Ohm; Prashant Mali; Leander Van Neste; David M Berman; Liang Liang; Kurinji Pandiyan; Kimberly J Briggs; Wei Zhang; Pedram Argani; Brian Simons; Wayne Yu; William Matsui; Wim Van Criekinge; Feyruz V Rassool; Elias Zambidis; Kornel E Schuebel; Leslie Cope; Jonathan Yen; Helai P Mohammad; Linzhao Cheng; Stephen B Baylin
Journal:  Cancer Res       Date:  2010-09-14       Impact factor: 12.701

5.  Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia.

Authors:  Marina Cavazzana-Calvo; Emmanuel Payen; Olivier Negre; Gary Wang; Kathleen Hehir; Floriane Fusil; Julian Down; Maria Denaro; Troy Brady; Karen Westerman; Resy Cavallesco; Beatrix Gillet-Legrand; Laure Caccavelli; Riccardo Sgarra; Leila Maouche-Chrétien; Françoise Bernaudin; Robert Girot; Ronald Dorazio; Geert-Jan Mulder; Axel Polack; Arthur Bank; Jean Soulier; Jérôme Larghero; Nabil Kabbara; Bruno Dalle; Bernard Gourmel; Gérard Socie; Stany Chrétien; Nathalie Cartier; Patrick Aubourg; Alain Fischer; Kenneth Cornetta; Frédéric Galacteros; Yves Beuzard; Eliane Gluckman; Frederick Bushman; Salima Hacein-Bey-Abina; Philippe Leboulch
Journal:  Nature       Date:  2010-09-16       Impact factor: 49.962

6.  Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency.

Authors:  Frederick Anokye-Danso; Chinmay M Trivedi; Denise Juhr; Mudit Gupta; Zheng Cui; Ying Tian; Yuzhen Zhang; Wenli Yang; Peter J Gruber; Jonathan A Epstein; Edward E Morrisey
Journal:  Cell Stem Cell       Date:  2011-04-08       Impact factor: 24.633

7.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.

Authors:  Marion G Ott; Manfred Schmidt; Kerstin Schwarzwaelder; Stefan Stein; Ulrich Siler; Ulrike Koehl; Hanno Glimm; Klaus Kühlcke; Andrea Schilz; Hana Kunkel; Sonja Naundorf; Andrea Brinkmann; Annette Deichmann; Marlene Fischer; Claudia Ball; Ingo Pilz; Cynthia Dunbar; Yang Du; Nancy A Jenkins; Neal G Copeland; Ursula Lüthi; Moustapha Hassan; Adrian J Thrasher; Dieter Hoelzer; Christof von Kalle; Reinhard Seger; Manuel Grez
Journal:  Nat Med       Date:  2006-04-02       Impact factor: 53.440

8.  Reprogramming of human somatic cells to pluripotency with defined factors.

Authors:  In-Hyun Park; Rui Zhao; Jason A West; Akiko Yabuuchi; Hongguang Huo; Tan A Ince; Paul H Lerou; M William Lensch; George Q Daley
Journal:  Nature       Date:  2007-12-23       Impact factor: 49.962

9.  In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state.

Authors:  Marius Wernig; Alexander Meissner; Ruth Foreman; Tobias Brambrink; Manching Ku; Konrad Hochedlinger; Bradley E Bernstein; Rudolf Jaenisch
Journal:  Nature       Date:  2007-06-06       Impact factor: 49.962

10.  Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures.

Authors:  Bin-Kuan Chou; Prashant Mali; Xiaosong Huang; Zhaohui Ye; Sarah N Dowey; Linda Ms Resar; Chunlin Zou; Y Alex Zhang; Jay Tong; Linzhao Cheng
Journal:  Cell Res       Date:  2011-01-18       Impact factor: 25.617

View more
  15 in total

1.  Micropattern size-dependent endothelial differentiation from a human induced pluripotent stem cell line.

Authors:  Sravanti Kusuma; Quinton Smith; Amanda Facklam; Sharon Gerecht
Journal:  J Tissue Eng Regen Med       Date:  2015-01-30       Impact factor: 3.963

2.  Engineering Human Stem Cell Lines with Inducible Gene Knockout using CRISPR/Cas9.

Authors:  Yuejun Chen; Jingyuan Cao; Man Xiong; Andrew J Petersen; Yi Dong; Yunlong Tao; Cindy Tzu-Ling Huang; Zhongwei Du; Su-Chun Zhang
Journal:  Cell Stem Cell       Date:  2015-07-02       Impact factor: 24.633

Review 3.  Promise and challenges of human iPSC-based hematologic disease modeling and treatment.

Authors:  Zhaohui Ye; Bin-Kuan Chou; Linzhao Cheng
Journal:  Int J Hematol       Date:  2012-05-23       Impact factor: 2.490

4.  Production of Gene-Corrected Adult Beta Globin Protein in Human Erythrocytes Differentiated from Patient iPSCs After Genome Editing of the Sickle Point Mutation.

Authors:  Xiaosong Huang; Ying Wang; Wei Yan; Cory Smith; Zhaohui Ye; Jing Wang; Yongxing Gao; Laurel Mendelsohn; Linzhao Cheng
Journal:  Stem Cells       Date:  2015-05       Impact factor: 6.277

5.  A simple and efficient system for regulating gene expression in human pluripotent stem cells and derivatives.

Authors:  Kun Qian; Cindy Tzu-Ling Huang; CindyTzu-Ling Huang; Hong Chen; Lisle W Blackbourn; Yuejun Chen; Jingyuan Cao; Lin Yao; Cornall Sauvey; Zhongwei Du; Su-Chun Zhang
Journal:  Stem Cells       Date:  2014-05       Impact factor: 6.277

Review 6.  Efficient and scalable expansion of human pluripotent stem cells under clinically compliant settings: a view in 2013.

Authors:  Ying Wang; Linzhao Cheng; Sharon Gerecht
Journal:  Ann Biomed Eng       Date:  2013-10-17       Impact factor: 3.934

7.  Flowing through the CRISPR-CAScade: Will genome editing boost cell therapies?

Authors:  Uri Ben-David
Journal:  Mol Cell Ther       Date:  2013-11-06

8.  Efficient CRISPR/Cas9-Mediated Versatile, Predictable, and Donor-Free Gene Knockout in Human Pluripotent Stem Cells.

Authors:  Zhongliang Liu; Yi Hui; Lei Shi; Zhenyu Chen; Xiangjie Xu; Liankai Chi; Beibei Fan; Yujiang Fang; Yang Liu; Lin Ma; Yiran Wang; Lei Xiao; Quanbin Zhang; Guohua Jin; Ling Liu; Xiaoqing Zhang
Journal:  Stem Cell Reports       Date:  2016-09-01       Impact factor: 7.765

Review 9.  Advanced Gene Manipulation Methods for Stem Cell Theranostics.

Authors:  Christopher Rathnam; Sy-Tsong Dean Chueng; Letao Yang; Ki-Bum Lee
Journal:  Theranostics       Date:  2017-07-08       Impact factor: 11.556

10.  Butyrate histone deacetylase inhibitors.

Authors:  Kosta Steliou; Michael S Boosalis; Susan P Perrine; José Sangerman; Douglas V Faller
Journal:  Biores Open Access       Date:  2012-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.